Sinovac Biotech Ltd. (NASDAQ: SVA) (“ SINOVAC ” or the “ Company ”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order ...
Special Meeting validly adjourned until the appropriate court makes a final decision on validity of the PIPE shares and will be reconvened SAIF and the Dissenting Investor Group’s deceptive claims of ...
Highlights bold steps to restore fairness to SINOVAC’s common shareholders and deliver long-term value creation Urges shareholders to VOTE the WHITE proxy card “AGAINST” the misguided proposals to ...
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today sent shareholders ...
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III ...
It is time to act. Your vote at the upcoming Special Meeting of Shareholders will shape SINOVAC’s future. SAIF has called this Special Meeting to reconstitute a remnant of the Former Board that the UK ...
BEIJING, Sept 24 (Reuters) - China's Sinovac Biotech expects to begin analysing final-stage human trial data on its coronavirus vaccine candidate this year to decide whether it is effective enough to ...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, ...
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results